// App-Quantinova.ai

: RITUXIMAB FOR THE PREVENTION OF ANEMIA POST ABO MAJOR INCOMPATIBLE ALLOGENEIC STEM CELL TRANSPLANTATION.

Researchers

Presenter

  • Maria Chiara Finazzi

Principal Investigators

  • Anna Grassi

  • Alessandra Weber

  • Chiara Pavoni

  • Caterina Mic

  • Daniela Taurino

  • Alessandro Rambaldi

Medical Centers

  • Department of Oncology and Hematology,Università degli Studi di Milano,Milano,Italy;Hematology and Bone Marrow Transplantation Unit,ASST Papa Giovanni XXIII,Bergamo,Italy

  • Department of Hematology, Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Multiple Myeloma

  • Aplastic anemia

  • Myelodysplastic Syndrome

  • Myelofibrosis

  • Lymphomas

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved